GPCR
Structure Therapeutics Inc. American Depositary Shares
Mentions (24Hr)
0.00% Today
Reddit Posts
GPCR-Eli Lilly Has New Obesity Drug Competitor in Structure Therapeutics
Top Gainers on Nasdaq & Crypto: Structure Therapeutics (GPCR) & Vector Space Biosciences (SBIO)
Mentions
Exactly, I agree on all points. I do think NVO will eventually acquire VKTX, or at least try. I mean, they tried with MTSR for a reason: their CEO understands NVO needs M&A to remain competitive. They could go the cheap way with GPCR/SMMT and not become competitive with LLY, or they could pay a higher premium in VKTX and have the possibility of becoming #1, surpassing LLY. As you said, the maintenance possibility with a placebo-like tolerability profile and great efficacy is basically unheard of. VKTX really has its hands on a great drug.
https://preview.redd.it/6leyc41glr6g1.png?width=2576&format=png&auto=webp&s=3ec8be2af93924540ef66866bd77445bc00d44ca Who else made mad money on GPCR!? HIT 95 on Monday.... 💎✋🏻
gap downs usually happen overnight thats how i filled GPCR @ 30 and sold on monday for 90 i bought 90/95 strangle for next week and will roll to 100 leaps if it does go below 90
Buy more Netflix and some of that GPCR
I forgot i had limit set for GPCR filled just 100 shares at 30 overnight sold for 90 this morning easy 6k in a day
Was planning to buy some GPCR this morning. Open trading app —> hate myself for not buying on Friday.
NVO just lost the MTSR deal. NVO needs another obesity asset to remain competitive vs. LLY. The only options left are GPCR (WL not competitive, same for tolerability) and VKTX. NVO already tried to acquire VKTX but didn't offer enough. Then, they turned around and tried to acquire MTSR (way lower cost vs VKTX) and were not successful. They will bid on VKTX soon, again, probably something like 18B which is a lowball. They will need to, as their CEO said this week, "dig deep in their pockets" for an appropriate 30B offer. Then, they may get back their #1 spot on the leaderboard and get ahead of LLY. If this scenario happens, my expectations are as follows: VKTX +600% by 2026 NVO +400% (share price of $225) by 2030.
I don't really like aleniglipron, it's a small molecule and has a safety profile that's less clean, along with a lower efficacy than Viking's VK2735. Peptides (like VK2735, tirzepatide, semaglutide) are easy to understand and to "guess" as for the predicted tolerability issues. It's not a bad buy especially at the current share price by any means, but I prefer VKTX. If VKTX gets suddenly bought out, I may buy into GPCR. The risk reward is less attractive in my eyes though.
I like biotech stocks or ETFs. One of the last high growth areas that hasn’t recovered. Names like NTLA VKTX GPCR still have lots of room to grow and AI is going to make everything cheaper and more efficient for doing research.
SEPN Septerna, Inc. (NASDAQ:SEPN) and Novo Nordisk today announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases. The companies will initially commence four development programmes for potential small molecule therapies directed to one or more select G protein-coupled receptor (GPCR) targets, including the GLP-1, GIP and glucagon receptors. Septerna is eligible to receive approximately 2.2 billion US dollars, including more than 200 million dollars in upfront and near-term payments Write to Benzinga at editorial@benzinga.com
Hey all - I aim to finish green in at least 2 of the following - $BTOG, $GPCR & $SOBR - gl to all!
[$CTTH](https://x.com/search?q=%24CTTH&src=cashtag_click) great patent news for their drug delivery system (Micelle) and the Diabetic drugs. [$NVO](https://x.com/search?q=%24NVO&src=cashtag_click) [$LLY](https://x.com/search?q=%24LLY&src=cashtag_click) [$AZN](https://x.com/search?q=%24AZN&src=cashtag_click) [$AMGN](https://x.com/search?q=%24AMGN&src=cashtag_click) [$VKTX](https://x.com/search?q=%24VKTX&src=cashtag_click) [$GPCR](https://x.com/search?q=%24GPCR&src=cashtag_click)
Jeffries named MGX and GPCR as strong buys with 1000% upside in a yahoo article yest. Could be it.
GPCR looks promising as they are trying to manufacture a wight loss pills https://finance.yahoo.com/news/why-structure-therapeutics-inc-gpcr-151517374.html
Half SMCI, half SOUN half ADMA, MRNA and GPCR. All regarded.
My second largest position is GPCR.. or should I say was my second largest before dropping 20%+
GPCR Structure Therapeutics GLP-1 obesity play is up 11% today. They are going to be presenting at obesity week this Sunday. I wonder what they are going to say. Anyone buying on the rumor?
If you really believe in the GLP-1 trade, then VKTX, GPCR, or LLY might be a better bet.
I like the stock, but $20/$30 in a few weeks is very strong. TERN, GPCR, VKTX, also worth a look if you want a basket of GLP-1 style treatments that aren’t either NVO or LLY. VKTX have data coming out soon that could put some near-term pressure on ALT, TERN, etc. though, so leave some room to average down over the next week or two.
could be a fun bet. complete casino play given it isn't in p3 yet but that's just how the drug industry works. drug not being well received puts it in GPCR territory for me tho lol, even worse if it isn't an oral... "efficacy is all that matters" GPCR after it turns out half the people in the trial throwing up uncontrollably lmao
TERN ALT GPCR probably all overvalued by at least 30% from these levels. TERN you have some time to jump in
It's in phase 1, with an average weight loss of 6.1% within four weeks. Competition: 1. $GPCR reports 6.2% average placebo-adjusted weight loss after 12 weeks from its pill in a Phase 2 trial. 2. $LLY reports orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks. At a glance, Roche's offering seems more effective but less mature in terms of R&D.
$GPCR July 19 $40 puts 🚨
Viking Therapeutics Inc. (VKTX) Structure Therapeutics Inc. (GPCR) Roche Holding AG (OTC: RHHBY)
You have to look at the balance sheet, income statement and kind of make an educated guess. Also analyze the situation. For instance, I INSM's dilution occurred at $52 and it's over $60 now. Unimpacted. GPCR is another one which diluted and hurt the stock a little bit but not much when looking at that rally. VKTX is one that dropped substantially after its raise. But notice the difference between these stocks and something like GWAV or BDRX
Kids need to stop gambling on meme stocks and find companies with actual growth potential. GPCR > Gamething.
KYTX and GPCR. Clickbait is lame.
I looked at GPCR today because of some regarded article but chose not to pull the trigger 
It says GPCR is an ADR, but HQ in California, how does that work? 
$GPCR Bearish 🩸 https://preview.redd.it/882c8sf1ce4d1.jpeg?width=1170&format=pjpg&auto=webp&s=d2d8be8c399b0390f2af6d3118e8910746bf8e29
$GPCR June 21 $50 puts ❌
$GPCR should dump below $50 soon 📉
Of course I sold covered calls in GPCR at 45 
$GPCR June 21 $50 puts 💀
$GPCR June 21 $45 puts 💀
$GPCR, Structure Theraputics, is another solid play at $1.6B market cap. Also, ALT is absolutely diluting their shares. https://www.macrotrends.net/stocks/charts/ALT/altimmune/shares-outstanding This past quarter, share count rose 50%.
Just to be clear - I have no idea what im doing but I bought GPCR a couple days ago. but it's already up 8% today, so be warned!\~
Buying VKTX PUTS every week. They are no where near (time wise) FDA approval for their obesity GLP-1 med. By the time they are in the market, Eli Lilly, Novo Nordisk and GPCR will have their oral med on the market.
I take Wegovy, but I want to switch to Zepbound because it is the superior product. More weight loss with fewer side effects. LLY is the way to go, but NVO has the much stronger brander name with Ozempic. I own $40k of both, plus $15k of each VKTX and GPCR in case they launch a strong competitor product and get acquired.
Given what we just saw from Novo’s CagriSema oral the other day (13% weight loss after 13 weeks), PFE has a massive uphill battle to show anything competitive. They might just be forced to buy VKTX or GPCR instead since PFE R&D has the track record the Titanic.
Small companies other than Novo Nordisk and Eli Lilly who will invent a new weight loss drug to compete with the current duopoly. See VKTX and to a lesser extent GPCR. The market for it is massive.
Yeah VKTX, ALT, GPCR are the 3 LLY/NVO competitors I track. Those 3 can break the obesity drug monopoly.
It's close to being technically oversold, isn't quite there yet. Is probably moderately overhated but I still don't like it: I really am of the view that there are too many good companies out there that when it comes to something like Pfizer, which has underperformed over 1, 5, 10, 20 year periods, why am I allocating to something that has disappointed repeatedly over such a long period? Something that seems cheap can often get cheaper and something that has repeatedly been underwhelming can continue to be so. There were a lot of people who bought/pumped PFE instead of LLY on r/stocks last year because "they're cheap and they have an obesity drug, too!" Then the obesity drug trial failed. Then 2-3 weeks later they took down FY24 guidance. Get in a really good new management team to overhaul Pfizer and I'd be interested. Pfizer with no catalyst and the company as is, maybe you get a bounce but for all the discussion over the last year about it, I've yet to read a case for why the next 5 years are going to be any different than the last 5-10-20. They failed on the obesity drug trial, so it wouldn't surprise me if they overpaid for one of the smaller players (VKTX, GPCR, etc.) You really have a situation with Pfizer where they got a ton of money from covid and the market clearly doesn't have any faith in their capital allocation ability, given past purchases (overpaying for SeaGen) and past purchases that didn't happen (the attempted Allergan purchase, which was blocked and then Abbvie eventually bought it for about half of what PFE was going to offer.) I've said it before, I'll say it again - it just feels like the Immelt-era GE of pharma, a stagnant dinosaur that isn't innovating. I dunno, maybe just me but when something has disappointed enough over a long enough period (again - I mean, w/Pfizer it's below where it was 20 years ago), I don't have any interest. If it materially changes (new management etc), I'll look but otherwise hard pass and if it does finally manage a bounce I'm more than okay with missing it because - as is - I don't see what sustains a bounce for PFE. Buffett said “It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price.” Calling Pfizer a fair company would be generous.
Haven't sold all recognized gains for 2023. See first post. CPA and I discussing end of year in general. He tells me no trading until 2024. He say's. "You need $3k net loss for 2023", I said okay... 30k was from this morning when Squibb bought RYZB. not selling yet. Added GPCR before close. From Google- *A capital gain or loss is generated from the difference between an asset's adjusted basis and the amount realized from the sale. The IRS allows investors to deduct up to $3,000 in capital losses per year. The $3,000 loss limit is the amount that can go against ordinary income.* Where he finds it, is his problem. Starting to see a pattern here.
LLY or GPCR should be the focus for pharma right now for what should be glaringly obvious reasons. Also REGN is better than Astra as well.
GPCR YOLO https://www.barrons.com/amp/articles/structure-therapeutics-stock-price-gpcr-15841232
Mkt cap is merely 2.4B, if the oral drug works and compete with ELI, it may easily go 20x. ELI is now 570B which is 250 times of GPCR